IMUX IMMUNIC, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1280776 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-24.5%
TTM EPS YoY135.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-223.2%
ROA-144.9%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets23.4%
Debt / equity0.00x
Current ratio4.28x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.75x
Accruals ratio-36.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $23.95M | $25.93M | $25.63M | $19.07M | $20.01M | $21.37M | $21.53M | $21.62M |
| SG&A expense | $19.42M | $9.40M | $7.61M | $4.26M | $5.98M | $5.71M | $5.29M | $4.01M |
| Operating income | -$43.37M | -$35.33M | -$33.23M | -$23.33M | -$25.99M | -$27.08M | -$26.82M | -$25.63M |
| Net income | -$42.31M | -$34.10M | -$32.59M | -$19.30M | -$25.58M | -$26.82M | -$25.47M | -$25.18M |
| EBITDA | -$43.33M | -$35.29M | -$33.20M | -$23.29M | -$25.95M | -$27.04M | -$26.78M | -$25.60M |
| EPS (basic) | -0.99 | -0.80 | -1.08 | — | -1.32 | -2.03 | -2.51 | — |
| EPS (diluted) | -0.99 | -0.80 | -1.08 | — | -1.32 | -2.03 | -2.51 | — |
| Dividends declared per share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted avg. shares (diluted) | 42.80M | 42.51M | 30.14M | — | 19.39M | 13.22M | 10.13M | — |
| Banking | ||||||||
| Provision for credit losses | $56,000 | $209,000 | $151,000 | $341,000 | $48,000 | $55,000 | $53,000 | -$121,000 |
| Balance sheet | ||||||||
| Cash & equivalents | $131.96M | $155.10M | $186.63M | $15.48M | $35.13M | $55.31M | $14.30M | $35.67M |
| Current assets | $135.09M | $157.83M | $188.76M | $22.87M | $39.27M | $59.84M | $18.98M | $39.33M |
| PP&E, net | $832,000 | $771,000 | $566,000 | $608,000 | $640,000 | $612,000 | $572,000 | $545,000 |
| Total assets | $136.42M | $159.17M | $189.74M | $24.05M | $40.70M | $61.43M | $20.52M | $40.87M |
| Current liabilities | $31.55M | $31.26M | $38.36M | $30.62M | $30.08M | $27.31M | $25.59M | $22.18M |
| Total liabilities | $31.95M | $31.59M | $38.51M | $30.73M | $30.20M | $27.52M | $25.80M | $22.44M |
| Shareholders' equity | $104.47M | $127.58M | $151.23M | -$6.67M | $10.50M | $33.91M | -$5.29M | $18.43M |
| Shares outstanding | 12.04M | 13.64M | 13.62M | 15.88M | 98.65M | 98.65M | 90.15M | 90.15M |
| Cash flow statement | ||||||||
| Operating cash flow | -$28.39M | -$31.00M | -$17.30M | -$19.28M | -$20.14M | -$24.61M | -$21.78M | -$22.96M |
| Capital expenditure | $104,000 | $249,000 | $2,000 | $11,000 | $67,000 | $36,000 | $47,000 | $3,000 |
| Free cash flow | -$28.49M | -$31.25M | -$17.30M | -$19.29M | -$20.21M | -$24.64M | -$21.82M | -$22.97M |
| Investing cash flow | -$104,000 | -$249,000 | -$2,000 | -$11,000 | -$67,000 | -$36,000 | -$47,000 | -$3,000 |
| Financing cash flow | $5.32M | $118,000 | $188.64M | $59,000 | $0 | $65.52M | $0 | $77,000 |
| Depreciation & amortization | $38,000 | $34,000 | $33,000 | $42,000 | $40,000 | $43,000 | $43,000 | $35,000 |
| Stock-based compensation | $13.91B | $6.78B | $4.47M | $1.31M | $3.61B | $1.90B | $2.04M | $1.99M |
Free plan shows the latest 8 periods; Pro shows all 55 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.